SEC Tracker
Get the app

iBio IBIO

iBio reports Q1 fiscal 2027 financial results

iBio (IBIO) filed an 8-K with the SEC on Nov 10, 2026, 4:36 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenues for Q1 2027 were $1.1 million, up from $0.1 million in Q1 2026.
  2. R&D expenses increased to $6.7 million in Q1 2027 from $3.6 million in Q1 2026.
  3. Cash and cash equivalents were $76.7 million as of September 30, 2026.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when iBio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.